🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. bevacizumab

    Outlook Therapeutics NL B. V.

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  2. bevacizumab

    Outlook Therapeutics NL B. V.

    Age-related Macular Degeneration

    phase 3 mab active

    4 trials

  3. mannitol and microcrystalline cellulose, Tolebrutinib

    Genzyme Europe B.V.

    Primary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  4. patisiran (ALN-TTR02)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 3 small molecule completed

    1 trial

  5. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

  6. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Non 24 Hour Sleep Wake Disorder

    phase 3 small molecule active

    4 trials

  7. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Smith-Magenis Syndrome

    phase 3 small molecule completed

    1 trial

  8. tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  9. A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

    uniQure biopharma B.V.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 other active

    1 trial

  10. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  11. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Acute Postoperative Pain

    phase 2 small molecule completed

    1 trial

  12. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

  13. ACP-103

    Acadia Pharmaceuticals B.V.

    Hallucinations

    phase 2 small molecule completed

    1 trial

  14. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  15. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  16. ACP-211

    Acadia Pharmaceuticals B.V.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  17. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  18. AG-348

    Agios Netherlands B.V.

    Thalassemia

    phase 2 small molecule active

    1 trial

  19. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  20. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  21. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

  22. ALN-6400

    Alnylam Netherlands B.V.

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  23. ALN-6400

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia

    phase 2 small molecule active

    1 trial

  24. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources